[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bassett Healthcare\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100635701","phase-4-the-vancomycin-piperacillintazobactam-vpt-patient-safety-trial-vps-100635701",false,"NCT07556107","The Vancomycin Piperacillin\u002FTazobactam (VPT) Patient Safety Trial (VPS)","A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin\u002FTazobactam or Meropenem: VPT Patient Safety (VPS) Study","VPS","Inclusion criteria\n\n1. Hospitalized or being hospitalized.\n2. Age \\>\u002F=18 yr old.\n3. Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician.\n4. Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively).\n5. Consenting\u002Fenrollment will not clinically significantly delay abx administration.\n6. Baseline and \\>\u002F=1 prior Scr available (within 1 yr).\n7. Pt or LAR able to provide IC. Exclusion criteria\n\n1\\. AKI (\\>\u002F=moderate) (KDIGO stage 2-3) (Scr increase \\>\u002F=2-fold from chronic BL) (Scr based).\n\n2\\. CKD (\\>\u002F=moderately to severely decreased eGFR) (KDIGO stage G3b-G5) (by history or eGFR \\\u003C\u002F=44 mL\u002Fmin\u002F1.73M2) (Scr based).\n\n3\\. Beta lactam allergy. 4. Contraindication to VPT or VM. 5. Infection requiring VPT or VM specifically or another abx regimen. 6. Participation in another research study with interventions that may impact study endpoints.","ALL","18 Years",{"count":20,"type":21},852,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.",[27,28,29],"Infection","Acute Kidney Injury","Sepsis",[31,32,33,34,35,36,37,38],"infection","hospitalized","AKI","cystatin c","vancomycin","piperacillin\u002Ftazobactam","meropenem","RCT","NOT_YET_RECRUITING","2026-04-22",{"date":42,"type":43},"2026-04-29","ACTUAL",{"date":45,"type":21},"2026-06-01",{"date":47,"type":21},"2028-12-31",{"name":49,"class":50},"Bassett Healthcare","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":51},"100381368","feasibility-of-non-operative-management-of-rectal-cancer-in-a-rural-population-100381368","NCT04245683","Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population","Inclusion Criteria:\n\nFor a patient to be considered eligible for this study, ALL of the following conditions must be met:\n\n1. Age 18 or greater\n2. ECOG PS 0-2\n3. Stage II or III, newly diagnosed, biopsy proven, rectal cancer\n4. No prior treatment for rectal cancer\n5. No prior pelvic radiotherapy\n6. Willing to undergo study related testing and monitoring after treatment\n7. Women of childbearing potential must rule out pregnancy within 2 weeks prior to registration with a blood test or urine study\n8. Women must not be pregnant or breastfeeding\n9. Able to provide informed consent\n\nExclusion Criteria:\n\nPatients are NOT considered eligible for this study if any of the following conditions apply:\n\n1. Patients with metastatic disease\n2. Patients that are not candidates for surgery\n3. Patients that refuse neoadjuvant treatment",{"count":59,"type":21},50,"OBSERVATIONAL","This is an observational research study. Patients with rectal cancer can choose different courses of treatment. This study will follow these patients over the course of approximately six years, depending on their treatment. Patients will be monitored through clinic visits and survey assessments to see how they do, how they feel regarding their treatment choices, and their outcomes. The surveys will analyze the impact of the patients' treatment choices, as well as patient adherence, in a rural setting.",[63],"Rectal Cancer","RECRUITING","2023-03-03",{"date":67,"type":43},"2023-03-07",{"date":69,"type":43},"2020-02-01",{"date":71,"type":21},"2027-08-01",{"name":49,"class":50},""]